MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1016/j.bbmt.2009.09.002

Медицинская библиотека · Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation · 2009

Low nonrelapse mortality and prolonged long-term survival after reduced-intensity allogeneic stem cell transplantation for relapsed or refractory diffuse large B cell lymphoma: report of the Société Française de Greffe de Moelle et de Thérapie Cellulaire.

Sirvent Anne, Dhedin Nathalie, Michallet Mauricette, Mounier Nicolas, Faucher Catherine, Yakoub-Agha Ibrahim, Mohty Mohamad, Robin Marie, Tabrizi Reza, Clement Laurence, Bilger Karin, Larosa Fabrice, Contentin Nathalie, Huyn Anne, François Sylvie, Bulabois Claude-Eric, Ceballos Patrice, Bourrhis Jean-Henri, Buzyn Agnès, Cornillon Jérôme, Guillerm Gaelle, de Revel Thierry, Bay Jacques-Olivier, Guilhot François, Milpied Noël

СтатьяМногоцентровое исследованиеПеревод в очереди

Аннотация

Patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) have a very poor prognosis. However, they may achieve long-term survival by undergoing allogeneic stem cell transplantation (SCT). The purpose of this study was to assess the outcome of all adult patients with DLBCL whose treatment included a reduced-intensity conditioning (RIC) regimen for allogeneic SCT and whose data were reported in the French Society of Marrow Transplantation and Cellular Therapy registry. Sixty-eight patients (median age: 48 years) were transplanted from October 1998 to January 2007. They had received a median of 2 regimens of therapy prior to allogeneic SCT, and 54 (79%) had already undergone SCT. Prior to transplantation, 32 patients (47%) were in complete remission (CR). For all patients but 1, conditioning regimens were based on fludarabine (Flu), which was combined with other chemotherapy drugs in 50 cases (74%) and with total body irradiation (TBI) in 17 (25%). For 56 patients (82%), the donor was an HLA-matched sibling, and peripheral blood was the most widely used source of stem cells (57 patients, 84%). With a median follow-up of 49 months, estimated 2-year overall survival (OS), progression-free survival (PFS), and the cumulative incidence of relapse were 49%, 44%, and 41%, respectively. The 1-year cumulative incidence of nonrelapse mortality (NRM) was 23%. According to multivariate analysis, the patients in CR before transplantation had a significantly longer PFS and a lower CI of relapse than patients transplanted during partial remission or stable or progressive disease. These results suggest that reduced-intensity allergenic transplantation is an attractive therapeutic option for patients with high-risk DLBCL.

Для цитирования: Sirvent Anne, Dhedin Nathalie, Michallet Mauricette, Mounier Nicolas, Faucher Catherine, Yakoub-Agha Ibrahim, Mohty Mohamad, Robin Marie, Tabrizi Reza, Clement Laurence, Bilger Karin, Larosa Fabrice, Contentin Nathalie, Huyn Anne, François Sylvie, Bulabois Claude-Eric, Ceballos Patrice, Bourrhis Jean-Henri, Buzyn Agnès, Cornillon Jérôme, Guillerm Gaelle, de Revel Thierry, Bay Jacques-Olivier, Guilhot François, Milpied Noël. Low nonrelapse mortality and prolonged long-term survival after reduced-intensity allogeneic stem cell transplantation for relapsed or refractory diffuse large B cell lymphoma: report of the Société Française de Greffe de Moelle et de Thérapie Cellulaire.. Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation. 2009. DOI: 10.1016/j.bbmt.2009.09.002.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.